If you’re enrolled in a Medicare Advantage (Part C) plan instead of Original Medicare (parts A and B), your coverage will be at least the same as what’s offered under Medicare Part B.

A warning letter posted Tuesday by the Food and Drug Administration revealed quality control issues with Dexcom’s continuous glucose monitors. The FDA raised concerns with a design change to a ...

The Food and Drug Administration on Tuesday released a warning letter that it sent to medical device company Dexcom on March 4 citing quality issues at the facilities responsible for testing its ...

Dexcom is preparing to launch a 15-day version of its G7 continuous glucose monitor, based on data presented Thursday at the Advanced Technologies & Treatments for Diabetes conference. Dexcom pointed ...

The Dexcom 15-day G7 continuous glucose monitor (CGM) is accurate and safe for use up to 15.5 days in adults with diabetes. Currently under review by the US Food and Drug Administration ...

To get a Dexcom G7 CGM through Medicare Part B ... plan instead of Original Medicare (parts A and B), your coverage may be equivalent to Original Medicare. As Part C plans are private, check ...

A survey conducted by the continuous glucose monitor maker Dexcom found that just over half of healthcare providers ranked technology and education as having larger impacts when it comes to ...

DexCom, Inc. (NASDAQ: DXCM), a global leader in glucose biosensing, today announced the launch of its first multi-region report, the "Dexcom State of Type 2 Report: Access and Attitudes Across ...

At the conference, first-ever accuracy and performance data will be presented for Dexcom’s upcoming G7 15 Day system, 1 showing an overall mean absolute relative difference (MARD) of 8.0% ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...